Phenylglycine derivatives useful as serine protease inhibitors

US7122559B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Peter W. Glunz · Wilmington, US
• Gregory S. Bisacchi · Lawrenceville, US
• George C. Morton · Collegeville, US
• Alexandra Holubec · Yardley, US
• E. Scott Priestley · Hockessin, US
• Xiaojun Zhang · Hopewell, US
• Uwe D. Treuner · Etterzhausen, DE

Key dates

• Filing date: Feb 10, 2004
• Grant date: Oct 17, 2006
• Expiry date: Jun 4, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds having the formula (I),or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is —NR6S(O)pR16; W is hydrogen or —(CR7R8)q—W1; W1 is hydrogen or a bond with R6; Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R1, R2, R3, R6, R7, and R16 are as defined in the specification.